These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 15324515

  • 21. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
    Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C.
    Diabetes Obes Metab; 2002 May; 4(3):177-86. PubMed ID: 12047396
    [Abstract] [Full Text] [Related]

  • 22. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
    Ristic S, Collober-Maugeais C, Pecher E, Cressier F.
    Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
    [Abstract] [Full Text] [Related]

  • 23. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
    Tunis SL, Sauriol L, Minshall ME.
    Appl Health Econ Health Policy; 2010 Jul; 8(4):267-80. PubMed ID: 20578781
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B, Kragh N, McConnachie CC, Valentine WJ, Rossi MC, Montagnoli R.
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [Abstract] [Full Text] [Related]

  • 27. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients.
    Soegondo S, Subekti I, Luthariana L.
    Acta Med Indones; 2004 Jul; 36(3):142-7. PubMed ID: 15557683
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
    Beale S, Bagust A, Shearer AT, Martin A, Hulme L.
    Pharmacoeconomics; 2006 Jul; 24 Suppl 1():21-34. PubMed ID: 16800160
    [Abstract] [Full Text] [Related]

  • 29. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
    Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.
    Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
    [Abstract] [Full Text] [Related]

  • 30. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S67-73. PubMed ID: 15324518
    [Abstract] [Full Text] [Related]

  • 31. Insulin secretagogues.
    Davies MJ.
    Curr Med Res Opin; 2002 Aug; 18 Suppl 1():s22-30. PubMed ID: 12365816
    [Abstract] [Full Text] [Related]

  • 32. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M, Azoulay M, Greiner RA.
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [Abstract] [Full Text] [Related]

  • 33. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
    [Abstract] [Full Text] [Related]

  • 34. Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.
    Weaver JU, Robertson D, Atkin SL.
    Diabetes Obes Metab; 2004 Sep; 6(5):344-52. PubMed ID: 15287927
    [Abstract] [Full Text] [Related]

  • 35. Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets.
    Moses RG.
    Clin Ther; 2008 Mar; 30(3):552-4. PubMed ID: 18405794
    [Abstract] [Full Text] [Related]

  • 36. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.
    Samyshkin Y, Guillermin AL, Best JH, Brunell SC, Lloyd A.
    J Med Econ; 2012 Mar; 15 Suppl 2():6-13. PubMed ID: 22793669
    [Abstract] [Full Text] [Related]

  • 37. Advances in oral therapy for type 2 diabetes.
    Davis SN.
    Postgrad Med; 2000 May 15; 107(6 Suppl Key):16-20. PubMed ID: 19667506
    [Abstract] [Full Text] [Related]

  • 38. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
    Pratley RE, Foley JE, Dunning BE.
    Curr Pharm Des; 2001 Sep 15; 7(14):1375-97. PubMed ID: 11472274
    [Abstract] [Full Text] [Related]

  • 39. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA.
    Curr Med Res Opin; 2004 Aug 15; 20 Suppl 1():S5-26. PubMed ID: 15324513
    [Abstract] [Full Text] [Related]

  • 40. An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
    Simons WR, Hagan MA.
    Pharmacoeconomics; 2010 Aug 15; 28(9):765-80. PubMed ID: 20799756
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.